Stay updated with breaking news from Robert Rosenson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24 Data presented at European Atherosclerosis Society 92nd Congress and
29.05.2024 - Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with ... Seite 1
A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by M
A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.
Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.